|Press Release Source: Echo Therapeutics, Inc. On Tuesday January 25, 2011, 8:00 am EST|
FRANKLIN, Mass., Jan. 25, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board:ECTE.ob - News), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that the company has launched a corporate Twitter account and corporate Facebook Page. Twitter users can now follow Echo at http://www.twitter.com/echotx and Facebook users can visit Echo at http://www.facebook.com/echotx.
Echo joins other medical device companies who are utilizing social media to provide online communities and individuals with faster and more direct access to credible health information, resources, news, and events.
"As we move toward the anticipated commercialization of our products this year Echo is eager to communicate directly with the company's investors and with physicians and patients in order to share valuable information in a timely manner," said Echo's Chairman, President and CEO Patrick T. Mooney, M.D. "We are excited to enter the social media network by incorporating Twitter and Facebook into our broader communication efforts."
About Echo Therapeutics
Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.
***Disclaimer & Disclosure***: I make no guarantee as to the accuracy or validity of information in this message...